Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CAND1 in preparation of medicine for inhibiting myocardial cell hypertrophy, heart failure and myocardial fibrosis

A technology for myocardial fibrosis and heart failure, applied in the application of drugs for heart failure and myocardial fibrosis, to prepare the field of inhibiting cardiomyocyte hypertrophy, which can solve the problems of little knowledge about CAND1 research

Active Publication Date: 2020-10-27
HARBIN MEDICAL UNIVERSITY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, little is known about the role of CAND1 in the cardiovascular field

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CAND1 in preparation of medicine for inhibiting myocardial cell hypertrophy, heart failure and myocardial fibrosis
  • Application of CAND1 in preparation of medicine for inhibiting myocardial cell hypertrophy, heart failure and myocardial fibrosis
  • Application of CAND1 in preparation of medicine for inhibiting myocardial cell hypertrophy, heart failure and myocardial fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Protective effect of CAND1 transgenic mice on pathological cardiac hypertrophy

[0025] 1. Construction of CAND1 transgenic mice

[0026] To establish transgenic mice with high myocardial expression of CAND1: clone the CAND1 gene by RT-PCR, insert the gene downstream of the myocardial α-myosin heavy chain promoter, and construct the transgenic expression vector, namely: pPB[Exp]-alphaMHC_long>mCand1[NM_027994. 1], the carrier structure diagram is as follows figure 1 As shown, C57BL / 6J mice with high expression of CAND1 transgene in cardiomyocytes were established by microinjection.

[0027] The PCR primer sequences for constructing CAND1 transgenic mice are as follows:

[0028] Transgene PCR primer F1: 5'-AGAGCCATAGGCTACGGTGTA-3'

[0029] Transgene PCR primer R1: 5'-CAAGGCATTTGACAGCTAAGTTC-3';

[0030] Transgene PCR primer F2:5'-TGTTGAGCCACTGCGTGCTAC-3'

[0031] Transgene PCR primer R2:5'-AGCCAGAAGTCAGATGCTCAAGG-3'

[0032] The genotypes of the transgeni...

Embodiment 2

[0038] Example 2 Constructing CAND1 adenovirus vector and observing the therapeutic effect of CAND1 on pathological cardiac hypertrophy and heart failure

[0039] 1. Construction of CAND1 adenovirus vector

[0040] The CDS region information of the target gene CAND1 (NM_027994.1) was obtained from the NCBI website, the gene was transferred from the library, and cloned into the adenovirus system shuttle vector. Linearize the shuttle plasmid carrying the target gene fragment and co-transform it with the adenovirus large backbone plasmid for homologous recombination in specific Escherichia coli. Since the adenovirus backbone plasmid is ampicillin resistant, after homologous recombination with the shuttle plasmid, The ampicillin resistance is lost and the kanamycin resistance is expressed at the same time. Therefore, the adenovirus vector backbone recombinant can be screened out through the change of resistance, and the recombinant can be picked for enzyme digestion identification...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of CAND1 in preparation of a medicine for inhibiting myocardial cell hypertrophy, heart failure and myocardial fibrosis. The NCBI registration number of mRNA of CAND1 is NM _ 027994.1. The prepared medicine can only contain CAND1 and can also be prepared into a medicine compound which contains an effective dose of CAND1 and a pharmaceutically acceptable carrier,wherein the carrier can be virus, cholesterol, nanoparticles, chitosan, lipidosome and the like; the CAND1 is synthesized and wrapped by the carrier to prepare an injection preparation; and the injection preparation is used for treating myocardial hypertrophy, heart failure and myocardial fibrosis in an intravenous or intramuscular injection manner.

Description

technical field [0001] The invention relates to a new pharmaceutical application of CAND1 (Cullin-Associated And Neddylation-Dissociated Protein 1), in particular to the application of CAND1 in the preparation of drugs for inhibiting cardiomyocyte hypertrophy, heart failure and myocardial fibrosis, and the invention belongs to the field of biomedicine. Background technique [0002] Cardiac Hypertrophy is a pathological process shared by various cardiovascular diseases. Myocardium cells are an adaptive compensatory process in the early stage of hypertrophy, but as the heart is subjected to pressure and volume load for a long time, it will cause myocardial insufficiency. Blood, arrhythmia, reduction of myocardial adaptability, etc., will eventually lead to serious consequences such as heart failure and even sudden death. Therefore, the prevention and treatment of pathological myocardial hypertrophy has always been a hot issue in the field of cardiovascular disease research. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P9/04
CPCA61K38/1709A61P9/04
Inventor 潘振伟吕延杰李星达
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com